An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression

Paper. Downey AE, Szigeti B, Bradley ER et al.. The Journal of Clinical Psychiatry, 21 Sep 2026.

Tags: Human, Clinical trial, Psilocybin, Depression, Anxiety, Bipolar.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 10: Early pilots in veteran PTSD, phantom limb pain and bipolar II

12 US veterans with severe, treatment-resistant PTSD received two psilocybin sessions with therapy. There were no serious adverse events, and 75% were in remission a month later. Small pilots also tested psilocybin in phantom limb pain (9 people, placebo-controlled) and bipolar II depression (14 people, open-label).

How much weight it carries: Open-label or very small. These results justify larger trials; they don't show the treatment works. (Humans, n = 12, Open-label, Peer reviewed)

Weekly Science Digest, 19 Sep 2026 to 25 Sep 2026, finding 1: A population trials usually exclude

Psilocybin was tolerated in 14 people with bipolar II depression, with no mania reported.

The open-label, single-arm trial started at 10 mg and escalated to 25 mg if symptoms persisted, with therapy around each session. Cardiovascular changes were transient; the primary depression endpoint came 21 days after the final dose.

Read the original

—
Node—
Statuslive
Throughput—